Excessive Daytime Sleepiness Market to Observe Stupendous Growth During the Forecast Period (2022-2032) | Key Companies – Takeda, Theranexus, XW Pharma, Avadel, Axsome Therapeutics, Benevolent AI Bio

June 02 07:06 2023
Excessive Daytime Sleepiness Market to Observe Stupendous Growth During the Forecast Period (2022-2032) | Key Companies - Takeda, Theranexus, XW Pharma, Avadel, Axsome Therapeutics, Benevolent AI Bio
Delveinsight Business Research LLP
The Excessive Daytime Sleepiness therapeutic market in the 7MM was USD 4,946 million in 2021. As per DelveInsight, the Excessive Daytime Sleepiness Market is anticipated to evolve immensely in the coming years owing to the expected approval of emerging therapies, expansion in the label of current therapies, and the increasing patient population of EDS in the 7MM.

DelveInsight’s “Excessive Daytime Sleepiness Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Excessive Daytime Sleepiness market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Excessive Daytime Sleepiness drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Excessive Daytime Sleepiness treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Excessive Daytime Sleepiness: An Overview

Excessive Daytime Sleepiness (EDS) is characterized by difficulty to stay awake and alert during the major waking episodes of the day, with sleep occurring unintentionally or at inappropriate times of the wake period.

EDS is often associated with a wide range of illnesses including metabolic, cardiovascular, neurological, and psychiatric diseases but also with voluntary behaviors reflecting poor sleep and sleep debt, leading to disability and increased risk of mortality. EDS is also commonly associated with social and economic consequences, thus constituting a significant public health problem.

The International Classification of Sleep Disorders (ICSD-2) includes EDS as an essential feature for three diagnostic categories: narcolepsy, hypersomnia, and behaviorally induced insufficient sleep syndrome. However, it is also associated with a wide range of diseases, including psychiatric and neurological disorders, pulmonary, and cardiac conditions.

Excessive Daytime Sleepiness Market Key Facts

  • The therapeutic market of Excessive Daytime Sleepiness in the United States was USD 3,399 million in the year 2021.

  • With the expected launch of upcoming therapies, FT218 (Sodium Oxybate), AXS-12 (Reboxetine), and Xywav (in EU) for Excessive Daytime Sleepiness in Narcolepsy; THN102 for Excessive Daytime Sleepiness in PD, Xywav for Excessive Daytime Sleepiness in IH; Ozawade for Excessive Daytime Sleepiness in OSA, the total market of Excessive Daytime Sleepiness is expected to show a decent change in upcoming years especially for PD, and IH.

  • The therapeutic market of Excessive Daytime Sleepiness in Japan was observed to be USD 361 million in the year 2021.

  • In the 7MM, the total diagnosed prevalent population of Excessive Daytime Sleepiness in 7MM was observed to be 6,857,997 cases in 2021.

  • In 2021, the highest cases of Excessive Daytime Sleepiness were estimated from OSA, followed by Bipolar Disorder in the United States.

  • In 2021, there were approximately 2,047,802 diagnosed prevalent cases of Excessive Daytime Sleepiness in EU5. Germany accounted for the highest number of cases.

  • In 2021, Japan registered approximately 1,073,447 cases of Excessive Daytime Sleepiness. The majority of Excessive Daytime Sleepiness cases were reported in OSA.

Excessive Daytime Sleepiness Market

Excessive Daytime Sleepiness Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Excessive Daytime Sleepiness pipeline therapies. It also thoroughly assesses the Excessive Daytime Sleepiness market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the market trend for each marketed Excessive Daytime Sleepiness drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Excessive Daytime Sleepiness Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Excessive Daytime Sleepiness epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Excessive Daytime Sleepiness epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Excessive Daytime Sleepiness Epidemiology, Segmented as –

  • Total Diagnosed Prevalent Cases of EDS in the 7MM [2019–2032]

  • Total Diagnosed Prevalent Cases of EDS in Different Disorders in the 7MM [2019–2032]

Excessive Daytime Sleepiness Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Excessive Daytime Sleepiness market or expected to be launched during the study period. The analysis covers the Excessive Daytime Sleepiness market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Excessive Daytime Sleepiness drugs based on their sale and market share.

The report also covers the Excessive Daytime Sleepiness pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Excessive Daytime Sleepiness companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Excessive Daytime Sleepiness Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/excessive-daytime-sleepiness-eds-market

Excessive Daytime Sleepiness Therapeutics Analysis

Companies across the globe are diligently working toward the development of novel therapies for EDS with a considerable amount of success over the years. Currently, Balance Therapeutics is leading the therapeutics market with its Excessive Daytime Sleepiness drug candidates in the most advanced stage of clinical development.

Excessive Daytime Sleepiness Companies Actively Working in the Therapeutics Market Include

  • Avadel Pharmaceutical

  • Axsome Therapeutics

  • Balance Therapeutics

  • Benevolent AI Bio

  • Bioprojet Pharma

  • Harmony Biosciences

  • Jazz Pharmaceuticals

  • NLS Pharma Ltd

  • Suven Life Sciences

  • Takeda Pharmaceuticals

  • Theranexus

  • XWPharma

And Many Others

Emerging and Marketed Excessive Daytime Sleepiness Therapies Covered in the Report Include:

  • Pentetrazol: Balance Therapeutics

  • TAK 925: Takeda Pharmaceuticals

  • FT218 (Sodium Oxybate): Avadel Pharmaceutical

  • AXS-12 (Reboxetine): Axsome Therapeutic

  • Wakix/ Ozawade (Pitolisant): Bioprojet Pharma/ Harmony Biosciences

  • Sunosi (Solriamfetol): Jazz Pharmaceuticals

And many more

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

https://www.delveinsight.com/sample-request/excessive-daytime-sleepiness-eds-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Excessive Daytime Sleepiness Competitive Intelligence Analysis

4. Excessive Daytime Sleepiness Market Overview at a Glance

5. Excessive Daytime Sleepiness Disease Background and Overview

6. Excessive Daytime Sleepiness Patient Journey

7. Excessive Daytime Sleepiness Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Excessive Daytime Sleepiness Treatment Algorithm, Current Treatment, and Medical Practices

9. Excessive Daytime Sleepiness Unmet Needs

10. Key Endpoints of Excessive Daytime Sleepiness Treatment

11. Excessive Daytime Sleepiness Marketed Therapies

12. Excessive Daytime Sleepiness Emerging Drugs and Latest Therapeutic Advances

13. Excessive Daytime Sleepiness Seven Major Market Analysis

14. Attribute Analysis

15. Excessive Daytime Sleepiness Market Outlook (In US, EU5, and Japan)

16. Excessive Daytime Sleepiness Companies Active in the Market

17. Excessive Daytime Sleepiness Access and Reimbursement Overview

18. KOL Views on the Excessive Daytime Sleepiness Market

19. Excessive Daytime Sleepiness Market Drivers

20. Excessive Daytime Sleepiness Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/excessive-daytime-sleepiness-eds-market

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

 

Other Trending Healthcare Reports by DelveInsight

Bone Neoplasms Market

“Bone Neoplasms Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Bone Neoplasms market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Bone Neoplasms market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

view more articles

About Article Author